Top Markets
Coin of the day
Connect Biopharma Holdings Limited Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

CNTB
Clasificación en acciones #19722
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical... Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Precio por acción
$2.42
Última sincronización: 2026-08-25
Capitalización bursátil
$152.37M
Cambio (1 día)
5.22%
Cambio (1 año)
39.88%
País
US
Comercio Connect Biopharma Holdings Limited (CNTB)

Categoría

Ganancias de Connect Biopharma Holdings Limited (CNTB)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Connect Biopharma Holdings Limited, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Connect Biopharma Holdings Limited desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH